ANNUAL DECLARATION OF INTERESTS (ADoI)

(Please note that high quality of scientific expertise is by nature based on prior experience and that therefore having an interest does not necessarily mean having a conflict of interest)

Name: VAN LOVEREN, Henk
Title: Prof.
Profession: Immunotoxicologist

Current EFSA involvements: Member-CONTAM Panel 2012-2015 (CONTAM), Member-BPA Toxicology 2012 WG (CEF), Member-Claims 2012-2015 (NDA), Member-Food Allergy 2012-2015 (NDA), Member-Novel Foods 2012-2015 (NDA)

Nature of Activities	Period	Organisation	Subject matter
I. Economic interest			NO INTEREST
II. Member of a management body or equivalent structure			NO INTEREST

CONTAM = Contaminants in the Food Chain; CEF = Food Contact Materials, Enzymes, Flavourings and Processing Aids; NDA = Dietetic Products, Nutrition and Allergies

III. Member of a scientific advisory body	01/2011 - now	-Name: Dutch Health Council	Member of an expert committee on Risk Assessment Children The committee forms an opinion based on an exploration of s litterature data to conclude whether or not perinatal exposure to environmental chemicasl poses an additional risk to the health of chemicals. The excercize does not focus on a specific pollutant. In general terms, the outcome of this excercize may have an impact on risk evaluations, including those that may be done within the CONTAM Panel, as any progressing science should have. The aim of the committee is to reach consensus, but minority opinions are possible. The advice is given to the Dutch Government.
	01/2011 - now	-Name: Dutch Asthma Foundation	Scientific Advisory Board I am an expert in this advisory board. The purpose is to evaluate grant proposals in the field of asthma research. Usually these projects relate to diagnisis and/or treatment of asthma and mechanism studies of asthma, and seldomly, if at all, relate to food. Based on the advice of the committee, management of the Asthma foundation will rank project proposals for funding. I have voting rights in this excercize.
	01/2005 - now	-Name: Dutch Health Council	Committees on on Health of Aspects of Occupational Exposure. The aim is to set occupational exposure limits for agentst that are at the workplace. I am member of this committee. The aim is to find consensus within the expert group.
	02/2013 - 02/2013	-Name: EFSA, European Food Safety Authority, Italy, Parma	Member - Claims 2012 - 2015 (NDA)
	01/2010 - 02/2013	-Name: EFSA, European Food Safety Authority, Italy, Parma	Member - Novel Foods (NDA)
	01/2010 - 02/2013	-Name: EFSA, European Food Safety Authority, Italy, Parma	Member - Food Allergy (NDA)
	01/2010 - 02/2013	-Name: EFSA, European Food Safety Authority, Italy, Parma	Member - Claims (NDA)
	01/2011 - 07/2012	-Name: EFSA, European Food Safety Authority, Italy, Parma	Vice-Chair - NDA Panel 2009-2012 (NDA)
	01/2011 - 07/2012	-Name: EFSA, European Food Safety Authority, Italy, Parma	Chair - Claims/Sub-Working Group 1: Gut/Immune (NDA)
	04/2011 - 06/2012	-Name: EFSA, European Food Safety Authority, Italy, Parma	Hearing Expert - ANS Panel 2008-2011 (ANS)
	01/2010 - 06/2012	-Name: EFSA, European Food Safety Authority, Italy, Parma	Member - NDA Panel 2006-2009 (NDA)

	11/2009 - 07/2010	-Name: EFSA	Ad hoc meetings 1. allegenicity animals, GMO Panel, July 2010 2. Allergenicity allylisocyanate, ANS Panel, June 2010 3. Immunostimulation by Lutein, ANS Panle, November 2009
	01/2007 - 10/2009	-Name: Dutch Food and Consumer Safety Authority	Committee on risk assessment for children. The committee addressed the question whether for risk assessment of developmental effects of exposure to pesticides an additional safety factor would be required. I was member of the committee, and the aim was a consensus document. In case of disagreement, alternate opinios would have been possible (but did not occur). The outcome of the excercize was an advice that was presented to the Dutch government. Methodologically, the outcome of this committee may have a scientific impact on the work of the CONTAM Panel, but not in a direct sense on the evaluation of specific agents.
IV. Employment	05/2002 - now	-Name: Maastricht University	Teaching Within the curriculum Post doctoral training Toxicology I am responsible for the course on immunotoxicology, i.e. how to assess the consequences in terms of immunosuppression, allergy, and autoimmunity as a result of exposure to chemicals. Research My main research line at Maastricht University is the implementation of toxicogenomics in the field of Immunotoxicology. Smaller areas are: immunotoxicity of statins, immunotoxicity of nanomaterials, assessment of developmental immunotoxicity. My appointment with Maastricht University is 20% of my time. In the toxicogenomics project, which is about 50% of my time in Maastricht, work is carried out at the account of the Dutch Government (Netherlands Genomics Initiative), and in that project, 20% of the budget for the whole project is supplied by a number of companies (chemical, drug, testing). Model compounds are being used for the reserach but no specific products offered by the participating industries are being tested in the project, In my capacity at Maatricht University, a minority of the funding, i.e. less than 5%, offered in kind, originates from companies. Maastricht University is not performing formal risk assessments other than for scientific reasons. Maastricht Universiity is not responsible for risk management decisions

	08/1984 - now	-Name: Laboratory fir Health Protection Research (GBO), Sector of Food and Consumer Safety, National Institute of Public Health and the Environment	The National Institute of Public Health and the Enviornment (RIVM) is an agency that belongs to the Ministery of Public Health, Welfare and Sports, and carries out research at the account of the government. RIVM provides risk assessment to the Dutch Government and the Food and Consumer Safety Authority in he Netherlands. Risk management decisions are not taken by RIVM I am Employed as Head of the Section Immune Effects and Infection. I may be involved as a specialist in immunotoxicology for risk assessments made. My main focus is on research is oriented at innovating risk assessment. Extramural funding is only accepted when it comes from organisations such as other parts of the Dutch Government, EU, WHO. It is not allowed to carry out research that is financed by private organizations/companies.
V. Ad hoc or occasional consultancy	05/2008 - 07/2012	-Name: ILSI	Participation as expert/advisor to the ILSI Expert Group on Markers for Immuno-modulation The expert group explores the available information on how markers of the immune system can be interpreted in terms of clinical relevance, especially in terms of beneficial and adverse effects on the immune system. The immunomodulation expert group is under ILSI Taskforce of Nutrition and immunity. No specific products or agents that modulate the imune system are being considered by the working group. I was member of this expert group. The aim was to provide a consensus opinion, but there is no obligation to sign the outcome of the excercize.
VI. Research funding	01/2004 - now	-Name: Dutch “Voedsel en Waren Autoriteit (VWA)	Part of the (regular) funding of the National Institute of Public Health and the Eivironment (RIVM) comprises funding by the Dutch Food and Consumer Safety Authority (VWA). This work included a project on probiotics (untill 2008) and currently includes a project on food allergy. Eventually, the Dutch Food and Consumer Safety Authority will use the outcome of these projects for their own aims (control) and for advice to the Ministery of Public Helath, Welfare, and Soprts. No private funding is allowed in this context, hence the research (co-)funding I received from the private sector in the latest full budget year, and for the areas covered by the Panels, does not exceeds 25% of the total annual research budget that is managed by me.
	01/2010 - 12/2011	-Name: WHO/Foodborne Disease Burden Epidemiology Reference Group (FERG)	For the WHO an inventory was made on approaches how to evaluate the disease burden of peanut allergy. The research (co-)funding was not coming from private institutions, hence the funding that I received from the private sector in the latest full budget year, and for the areas covered by the Panels, does not exceeds 25% of the total annual research budget that is managed by me

VII. Intellectual property rights			NO INTEREST
VIII. Other membership or affiliation			NO INTEREST
IX. Other relevant interest	12/2009 - 12/2009	-Name: ILSI	ILSI workshop food health claims. This workshop was organised to discuss approaches for how to evaluate outcomes of studies of food in terms of beneficial effects. The workshop was not intended to any specific products. I took part as an expert taking part in he discussions. There was no outcome of the meeting for which I had to take responsibility. I believe the meeting was held in Montreux
X. Interests of close family members			NO INTEREST

I hereby declare that I have read both the Guidance Document on Declarations of Interests and the Procedure for identifying and handling potential conflict of interests and that the above Declaration of Interests is complete.

Date: 12/03/2013 Signature: SIGNED